Send us Feedback

NeuroMetrix (NURO)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
UPDATE: Neurometrix (NURO) Reports Large Order from Wal-Mart Canada
StreetInsider.com  Apr 2  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/UPDATE%3A+Neurometrix+%28NURO%29+Reports+Large+Order+from+Wal-Mart+Canada/7312439.html for the full story.
NeuroMetrix Reports Nasdaq Communication
Business Wire  Mar 23  Comment 
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, reported that it had received notice from The NASDAQ Stock Market indicating that the closing bid price
NeuroMetrix Initiative to Support American Diabetes Association Alert Day®
Business Wire  Mar 20  Comment 
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of neurological complications of diabetes announced a patient initiative to support American Diabetes Association Alert Day® which is March 27, 2012.
NeuroMetrix Announces Warrant Redemption
Business Wire  Mar 13  Comment 
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of neurological complications of diabetes, today announced plans to redeem warrants to purchase an aggregate of 1,430,480 shares of common stock, par
Dawson James Securities: NeuroMetrix Launches New Product
Benzinga  Feb 27  Comment 
According to a research report published today by Dawson James Securities, NeuroMetrix Inc. (NASDAQ: NURO) has launched its new product, the NC-stat DPNCheck, for diagnosing diabetic peripheral neuropathy. Dawson James Securities explained...
NeuroMetrix Reports Q4 2011 Results
Business Wire  Feb 15  Comment 
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today reported business and financial highlights for the quarter and year ended December 31, 2011. The
NeuroMetrix Announces Pricing of Securities Offering
Business Wire  Feb 8  Comment 
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has priced a public offering of up to 10,500,000 Units at a price per Unit of $1.00, for aggregate gross proceeds of up to $10,500,000, pursuant to its previously filed Registration Statement
NeuroMetrix (NURO) Prices 10.5 Million Unit Offering at $1/unit
StreetInsider.com  Feb 8  Comment 
NeuroMetrix (NURO) Gets Milestone 100th NC-stat DPNCheck Order
StreetInsider.com  Dec 28  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/NeuroMetrix+%28NURO%29+Gets+Milestone+100th+NC-stat+DPNCheck+Order/7044479.html for the full story.
NeuroMetrix (NURO) Files $10.5M Unit Shelf
StreetInsider.com  Nov 23  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/NeuroMetrix+%28NURO%29+Files+%2410.5M+Unit+Shelf/6974526.html for the full story.
NeuroMetrix (NURO) Appoints Kenneth Snow, M.D. as Chief Medical Officer
StreetInsider.com  Oct 4  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/NeuroMetrix+%28NURO%29+Appoints+Kenneth+Snow%2C+M.D.+as+Chief+Medical+Officer/6829163.html for the full story.




more ▼WIKI ANALYSIS
 
TOP CONTRIBUTORS
Sr. Director
Greg Aurand
www.zacks.com

NeuroMetrix is a science-based medical device company advancing patient care through the development and marketing of innovative medical devices products that aid physicians in the assessment and treatment of diseases and injuries of peripheral nerves, and that provide regional anesthesia and pain control. The company's primary offering is technologies for the assessment of neuropathies. Neuropathies are disorders that affect the peripheral nerves and occur for a variety of reasons, including nerve entrapment (carpal tunnel syndrome), systemic disorders (diabetes) and spinal disk herniation compressing spinal nerve roots. NeuroMetrix's initial neuropathy evaluation device, the NC-stat® System, has been on the market since May 1999 and is used in over 5,000 physician's offices and clinics in the United States for performance of nerve conduction studies. The ADVANCE™ NCS/EMG System is a comprehensive platform for the performance of traditional nerve conduction studies and needle electromyography procedures which is used by specialist physicians with peripheral nerve expertise.




References

Retrieved from "http://www.wikinvest.com/stock/NeuroMetrix_(NURO)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki